Noninferiority of Simplified Dolutegravir Monotherapy Compared to Continued Combination Antiretroviral Therapy That Was Initiated During Primary Human Immunodeficiency Virus Infection: A Randomized, Controlled, Multisite, Open-label, Noninferiority Trial | Zendy

Dominique L. Braun | Zendy; Teja Turk | Zendy; Fabian Tschumi | Zendy; Christina Grube | Zendy; Benjamin Hampel | Zendy; Carsten Depmeier | Zendy; Peter W. Schreiber | Zendy; Silvio D. Brugger | Zendy; Michael Greiner | Zendy; Daniela Steffens | Zendy; Cornelia De Torrenté-Bayard | Zendy; Perrine Courlet | Zendy; Kathrin Neumann | Zendy; Herbert Kuster | Zendy; Markus Flepp | Zendy; Barbara Bertisch | Zendy; Laurent A. Décosterd | Zendy; Jürg Böni | Zendy; Karin J. Metzner | Zendy; Roger D. Kouyos | Zendy; Huldrych F. Günthard | Zendy

Open Access

Noninferiority of Simplified Dolutegravir Monotherapy Compared to Continued Combination Antiretroviral Therapy That Was Initiated During Primary Human Immunodeficiency Virus Infection: A Randomized, Controlled, Multisite, Open-label, Noninferiority Trial

Author(s) -

Dominique L. Braun,

Teja Turk,

Fabian Tschumi,

Christina Grube,

Benjamin Hampel,

Carsten Depmeier,

Peter W. Schreiber,

Silvio D. Brugger,

Michael Greiner,

Daniela Steffens,

Cornelia De Torrenté-Bayard,

Perrine Courlet,

Kathrin Neumann,

Herbert Kuster,

Markus Flepp,

Barbara Bertisch,

Laurent A. Décosterd,

Jürg Böni,

Karin J. Metzner,

Roger D. Kouyos,

Huldrych F. Günthard

Publication year - 2018

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciy1131

Subject(s) - dolutegravir , medicine , human immunodeficiency virus (hiv) , antiretroviral therapy , randomized controlled trial , open label , virology , viral load

Patients who start combination antiretroviral therapy (cART) during primary human immunodeficiency virus type 1 (HIV-1) infection show a smaller HIV-1 latent reservoir, less immune activation, and less viral diversity compared to patients who start cART during chronic infection. We conducted a pilot study to determine whether these properties would allow sustained virological suppression after simplification of cART to dolutegravir monotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research